Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Public ClinicalTrials.gov record NCT00464633. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL
Study identification
- NCT ID
- NCT00464633
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 165 participants
Conditions and interventions
Conditions
Interventions
- alvocidib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2007
- Primary completion
- Nov 30, 2011
- Completion
- Nov 30, 2011
- Last update posted
- Feb 11, 2013
2007 – 2011
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sanofi-Aventis Investigational Site Number 840008 | San Diego | California | 92103 | — |
| Sanofi-Aventis Investigational Site Number 840022 | San Francisco | California | 94143 | — |
| Sanofi-Aventis Investigational Site Number 840010 | Chicago | Illinois | 60611 | — |
| Sanofi-Aventis Investigational Site Number 840012 | Chicago | Illinois | 60637 | — |
| Sanofi-Aventis Investigational Site Number 840017 | Indianapolis | Indiana | 46202 | — |
| Sanofi-Aventis Investigational Site Number 840001 | Boston | Massachusetts | 02115 | — |
| Sanofi-Aventis Investigational Site Number 840023 | Ann Arbor | Michigan | 48109-0759 | — |
| Sanofi-Aventis Investigational Site Number 840005 | New York | New York | 10021 | — |
| Sanofi-Aventis Investigational Site Number 840006 | New York | New York | 10029-6574 | — |
| Sanofi-Aventis Investigational Site Number 840003 | Durham | North Carolina | 27710 | — |
| Sanofi-Aventis Investigational Site Number 840018 | Cleveland | Ohio | 44106 | — |
| Sanofi-Aventis Investigational Site Number 840002 | Columbus | Ohio | 43210 | — |
| Sanofi-Aventis Investigational Site Number 840020 | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00464633, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2013 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00464633 live on ClinicalTrials.gov.